Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers

Carmela P. Morales, Stuart Jon Spechler

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

For patients found to have intestinal metaplasia at the gastroesophageal junction, technical problems can make it difficult to distinguish short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia. Whereas the risk of malignancy for the former condition seems to be higher than that for the latter, the distinction between these conditions can have practical clinical implications. Immunostaining for cytokeratins has been proposed as a means to distinguish intestinal metaplasia of esophageal and gastric origins. We review recent data on this issue, and conclude that immunostaining for cytokeratins has no clear advantages over other biomarkers that have been proposed for identifying Barrett's esophagus (e.g., mucin histochemistry, mAb Das-1 immunoreactivity). Presently, the importance of intestinal metaplasia at the gastroesophageal junction remains unclear, and the clinical utility of biomarkers in distinguishing short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia has not yet been established.

Original languageEnglish (US)
Pages (from-to)759-762
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume98
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Esophagogastric Junction
Metaplasia
Biomarkers
Barrett Esophagus
Bacteria
Stomach
Cardia
Keratins
Mucins
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Intestinal metaplasia at the gastroesophageal junction : Barrett's, bacteria, and biomarkers. / Morales, Carmela P.; Spechler, Stuart Jon.

In: American Journal of Gastroenterology, Vol. 98, No. 4, 01.04.2003, p. 759-762.

Research output: Contribution to journalArticle

@article{6ad639f22bdb4f11996207ed8b9d1eb2,
title = "Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers",
abstract = "For patients found to have intestinal metaplasia at the gastroesophageal junction, technical problems can make it difficult to distinguish short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia. Whereas the risk of malignancy for the former condition seems to be higher than that for the latter, the distinction between these conditions can have practical clinical implications. Immunostaining for cytokeratins has been proposed as a means to distinguish intestinal metaplasia of esophageal and gastric origins. We review recent data on this issue, and conclude that immunostaining for cytokeratins has no clear advantages over other biomarkers that have been proposed for identifying Barrett's esophagus (e.g., mucin histochemistry, mAb Das-1 immunoreactivity). Presently, the importance of intestinal metaplasia at the gastroesophageal junction remains unclear, and the clinical utility of biomarkers in distinguishing short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia has not yet been established.",
author = "Morales, {Carmela P.} and Spechler, {Stuart Jon}",
year = "2003",
month = "4",
day = "1",
doi = "10.1111/j.1572-0241.2003.07393.x",
language = "English (US)",
volume = "98",
pages = "759--762",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Intestinal metaplasia at the gastroesophageal junction

T2 - Barrett's, bacteria, and biomarkers

AU - Morales, Carmela P.

AU - Spechler, Stuart Jon

PY - 2003/4/1

Y1 - 2003/4/1

N2 - For patients found to have intestinal metaplasia at the gastroesophageal junction, technical problems can make it difficult to distinguish short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia. Whereas the risk of malignancy for the former condition seems to be higher than that for the latter, the distinction between these conditions can have practical clinical implications. Immunostaining for cytokeratins has been proposed as a means to distinguish intestinal metaplasia of esophageal and gastric origins. We review recent data on this issue, and conclude that immunostaining for cytokeratins has no clear advantages over other biomarkers that have been proposed for identifying Barrett's esophagus (e.g., mucin histochemistry, mAb Das-1 immunoreactivity). Presently, the importance of intestinal metaplasia at the gastroesophageal junction remains unclear, and the clinical utility of biomarkers in distinguishing short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia has not yet been established.

AB - For patients found to have intestinal metaplasia at the gastroesophageal junction, technical problems can make it difficult to distinguish short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia. Whereas the risk of malignancy for the former condition seems to be higher than that for the latter, the distinction between these conditions can have practical clinical implications. Immunostaining for cytokeratins has been proposed as a means to distinguish intestinal metaplasia of esophageal and gastric origins. We review recent data on this issue, and conclude that immunostaining for cytokeratins has no clear advantages over other biomarkers that have been proposed for identifying Barrett's esophagus (e.g., mucin histochemistry, mAb Das-1 immunoreactivity). Presently, the importance of intestinal metaplasia at the gastroesophageal junction remains unclear, and the clinical utility of biomarkers in distinguishing short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia has not yet been established.

UR - http://www.scopus.com/inward/record.url?scp=0037617427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037617427&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2003.07393.x

DO - 10.1111/j.1572-0241.2003.07393.x

M3 - Article

C2 - 12738452

AN - SCOPUS:0037617427

VL - 98

SP - 759

EP - 762

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -